Augenklinik, Universitätsklinikum Erlangen, Erlangen, Germany.
Klin Monbl Augenheilkd. 2021 Nov;238(11):1240-1247. doi: 10.1055/a-1328-2847. Epub 2021 Mar 17.
Up to now, no data have been available on the therapeutic success rate of Xen45 gel stent with respect to axial length (AL). The present study aimed to investigate a potential influence of AL on therapeutic success in stand-alone Xen45 gel stent implantation or combination with cataract surgery in open-angle glaucoma patients (OAG) with a follow-up of 2 years.
In this retrospective observational study, 98 eyes of 87 glaucoma patients of the Department of Ophthalmology, University of Erlangen Nürnberg, and from the Erlangen Glaucoma Registry (NCT00494923; ISSN 2191-5008, CS-2011) underwent stand-alone Xen45 gel stent implantation or a combination with cataract surgery. Therapeutic success was defined as ≥ 20% IOP reduction with the same or fewer anti-glaucomatous eye drops needed compared to baseline, yet without additional glaucoma-related surgery (expect bleb needling). Therapeutic failure was classified as any additional glaucoma-related surgery, IOP reduction < 20% or if more local anti-glaucomatous eye drops were applied compared to baseline.
The therapeutic success rate was 60.7% (1 year) and 62.5% (2 years). No statistical difference was observed when procedures were combined with cataract surgery (p > 0.05). Subgroup analysis yielded no significantly different therapeutic success when considering glaucoma subtype [1 year: 61.5% (POAG), 60% (SAOG), 2 years: 54.5% (POAG), 69.2% (SOAG); p > 0.05]. Anti-glaucomatous medication use was lowered from 2.72 ± 1.04 at baseline to 0.61 ± 0.99 (1 year) and 0.7 ± 1.04 (2 years). The therapeutic success rate was seen to be independent of axial length for group and subgroup analysis (p > 0.05). Emmetropic eyes (22.0 - 24.5 mm) showed a statistically higher needling rate than myopic eyes (> 24.5 mm, p = 0.02).
Minimal invasive glaucoma surgery is one therapeutic option in OAG eyes, with good reduction in IOP even after 24 months (with additional bleb needling). Therapeutic success seemed to be independent of axial length in the present study.
目前尚无关于 Xen45 凝胶支架在眼轴长度(AL)方面治疗成功率的数据。本研究旨在探讨在无晶状体眼合并白内障患者中,Xen45 凝胶支架单独植入或联合白内障手术治疗后,AL 对治疗成功率的潜在影响,随访时间为 2 年。
在这项回顾性观察研究中,共有 87 例青光眼患者的 98 只眼来自于德国埃尔朗根纽伦堡大学眼科系和埃尔朗根青光眼登记处(NCT00494923;ISSN 2191-5008,CS-2011),这些患者接受了 Xen45 凝胶支架单独植入或联合白内障手术。治疗成功定义为与基线相比,眼压降低 20%以上,同时所需的抗青光眼滴眼液相同或更少,但无需额外的青光眼相关手术(除外滤过泡针刺术)。治疗失败定义为任何额外的青光眼相关手术、眼压降低<20%或与基线相比使用更多的局部抗青光眼滴眼液。
治疗成功率为 60.7%(1 年)和 62.5%(2 年)。当手术与白内障手术联合时,没有观察到统计学差异(p>0.05)。亚组分析显示,考虑到青光眼亚型时,治疗成功率无显著差异[1 年:61.5%(POAG),60%(SAOG);2 年:54.5%(POAG),69.2%(SOAG);p>0.05]。抗青光眼药物的使用从基线时的 2.72±1.04 降低到 1 年时的 0.61±0.99 和 2 年时的 0.7±1.04。对于组和亚组分析,治疗成功率与眼轴长度无关(p>0.05)。正视眼(22.0-24.5mm)比近视眼(>24.5mm)需要进行滤过泡针刺术的概率更高,具有统计学意义(p=0.02)。
微创青光眼手术是治疗开角型青光眼眼的一种治疗选择,即使在 24 个月后,眼压也能得到很好的降低(需要额外的滤过泡针刺术)。在本研究中,治疗成功率似乎与眼轴长度无关。